Nivolumab and Hypofractionated Radiotherapy in Patients With Advanced Lung Cancer: ABSCOPAL-1 Clinical Trial

Nivolumab and Hypofractionated Radiotherapy in Patients With Advanced Lung Cancer: ABSCOPAL-1 Clinical Trial

BackgroundMore clinical practice need to be performed to verify the toxicity of the hypofractionated radiotherapy (HFRT) combined with PD-1 blockade in lung cancer. This phase I study aimed to investigate the safety and efficacy of nivolumab combined with HFRT in patients with progressive advanced l...

Full description

Bibliographic Details
Main Authors: Hua Ye, Haowen Pang, Xiangxiang Shi, Peirong Ren, Shangke Huang, Hong Yu, Jingbo Wu, Sheng Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
nivolumab
hypofractionated radiotherapy
advanced lung cancer
safety
efficacy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.657024/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.657024/full

Similar Items